Clinical Trial Update: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects [Phase 2]

View source ↗

Summary

A Phase 2 multiple ascending dose study of BMS-707035 in HIV-1 infected subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BMS-707035

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 2 | Status: WITHDRAWN